Merdury Biopharmaceutical Corporation

Merdury Biopharmaceutical Corporation is a health technology company specializing in the research, development, and commercialization of pharmaceutical products focused on addressing unmet medical needs. Established in 2019 and headquartered in New Taipei City, the company distinguishes itself through its proprietary StackDose™ technology platform, which integrates drug formulation, 3D powder printing, and related hardware and software to enable advanced, time-controlled drug release profiles in both instant and sustained-release tablet forms. This innovation is supported by a portfolio of multinational patents, underscoring the firm's commitment to technological leadership. Merdury's primary therapeutic areas include pharmaceuticals for cardiovascular, metabolic, neurological, and sexual health conditions, with notable products such as Sildenafil, Metformin, Tadalafil, Zolpidem, as well as treatments targeting angina, migraines, and complex antihypertensive needs. The company markets its drugs in Taiwan, the United States, and select international markets. By leveraging 3D printing technologies, Merdury aims to develop pharmaceuticals with optimized efficacy and lower side effect profiles, strengthening its role as a pioneer within the growing field of precision medicine and pharmaceutical manufacturing innovation.